RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary targeted LNP delivery platform. SHANGHAI and CAMBRIDGE, Mass., Aug. 8,...
NutriPQQ® Publishes New PQQ Sourcing Guide for Supplement Brands and Manufacturers
The new B2B resource helps procurement, formulation, and quality teams evaluate PQQ production methods, ingredient identity, testing, stability, packaging, and supply continuity. Key Highlights Provides a practical framework for comparing PQQ suppliers beyond quoted price and assay percentage. Covers production method, ingredient identity, analytical testing, batch consistency, formulation characteristics, packaging, storage, and supply continuity. Supports procurement, quality,...
Alebund’s AP301 NDA Accepted for Review by China’s NMPA
SHANGHAI, Aug. 7, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the New Drug Application (NDA) for AP301 capsules, a novel oral iron-based phosphate binder, for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving maintenance dialysis, is formally accepted for review by...
CityUHK ranked No.1 in Hong Kong in Nature Index 2026 Nanoscience and Nanotechnology Supplement
HONG KONG, Aug. 7, 2026 /PRNewswire/ -- City University of Hong Kong (CityUHK) has achieved another significant milestone in global research excellence. Following its earlier achievement of ranking 38th globally and 1st in Hong Kong in the "Nature Index 2026 Chemistry Supplement", CityUHK has reached new heights in the Nature Index. It secures a place among the "Leading...
Beyond Encouragement: Momcozy Calls for Breastfeeding Support That Works in Real Life
SYDNEY, Aug. 7, 2026 /PRNewswire/ -- This World Breastfeeding Week, Momcozy, the Global No.1 Wearable Breast Pump Brand trusted by more than five million mothers worldwide, launched Breathe & Breastfeed in Australia, a campaign advocating practical breastfeeding support that fits into mothers' everyday lives. From right to left: Momcozy Brand Representative Ellen Zhou, Midwife Bianca Burge, working mum...
STARCARES Revamps Basketball Court at the University of Lagos for Future Healthcare Professionals
The revitalised basketball court gives approximately 2,000 future healthcare professionals a dedicated space to recharge, connect, and build community activities beyond their academic training LAGOS, Nigeria, Aug. 7, 2026 /PRNewswire/ -- STARCARES, the community impact initiative of STARTRADER, has completed the redevelopment of the basketball court at the College of Medicine, University of Lagos, giving approximately 2,000 students...
Yochanra®, the World’s First Innovative Drug to Overcome FGFR Inhibitor Resistance, Makes Its Global Debut in China
NANJING, China and GAITHERSBURG, Md., Aug. 7, 2026 /PRNewswire/ -- TransThera Sciences' Yochanra® is the first drug independently developed in China to address the longstanding global challenge of acquired resistance to FGFR inhibitor therapy in patients with cholangiocarcinoma. On 6 August 2026, the National Medical Products Administration (the "NMPA") formally approved the drug for marketing. As a global...
CLASSYS Appoints Former Samsung Electronics and Vuno Executive Dr. Taek-Soo Kim as Chief Technology Officer, Accelerating Its Evolution into a Global Medical Aesthetics Technology Company
SEOUL, South Korea, Aug. 7, 2026 /PRNewswire/ -- CLASSYS (KOSDAQ: 214150), a global medical aesthetics platform company, announced the appointment of Dr. Taek-Soo Kim, a distinguished technology management expert, as its new Chief Technology Officer (CTO) and Head of Research and Development. Taek-Soo Kim, CLASSYS’s newly appointed Chief Technology Officer (CTO) and Head of Research and Development. (Photo: CLASSYS)...
Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
NANTONG, China, Aug. 6, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics, today announced the completion of patient enrollment and initial dosing across all cohorts in its Phase II clinical trial evaluating RAG-17, an investigational siRNA therapy targeting superoxide dismutase 1 (SOD1) mutations in amyotrophic lateral sclerosis (ALS). From the dosing of the first...
Harbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. Bob Zhang as President of Metabolic Disease Franchise. Dr. Zhang will...
